PROM1 and glioma: In established subcutaneous human xenograft tumors, AC133 NIR-PIT demonstrated significant tumor growth inhibition in CD133-expressing U251 glioma models, confirmed by reduced signal intensity post-NIR light exposure and diminished tumor volumes.